Akeylink Biotechnology to Speak at ACCESS ASIA Partnering Forum

September 25, 2025 (9:30 AM CST) — We’re pleased to announce that Kwangho Kim, Manager, Business Development of Aptamer, Sciences Inc., will present at the ACCESS Asia Partnering Forum Online Showcase. ACCESS Asia builds on the success of ACCESS China, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and partners

About Akeylink Biotechnology

Fujian Akeylink Biotechnology Co., Ltd. was established in 2021 in Shanghai, China, with a focus on developing novel drugs for treating viral infections and liver-related diseases. Akeylink is a spin-out company from Fujian Cosunter Pharmaceutical Co.,Ltd. (广生堂), a publicly listed company on Shenzhen Stock Exchange (ticker symbol: 300436) engaging in development and commercialization of generic drugs.

The company focuses on antiviral and liver disease treatments, with a strategically optimized product pipeline for both short- and long-term growth. Its oral small-molecule drug for COVID-19, a best-in-class 3CL protease inhibitor, has been launched in China, contributing to the nation’s pandemic response. Another prime asset of the company, GST-HG141, a novel HBV capsid assembly modulator (CAM) for the treatment of chronic hepatitis B, has shown promising results in Phase 2 clinical trials and has successfully advanced to Phase 3. Additionally, GST-HG131, a first-in-class oral HBsAg inhibitor for the treatment of chronic hepatitis B, has displayed excellent tolerability and safety profile in Phase 1 clinical trial and demonstrated robust efficacy in reducing HBsAg levels in a Phase 2 study. It is currently progressing rapidly into Phase 2b studies as a mono- or combination therapy.

About the speaker

Jimmy serves as Director of International Business Development at Akeylink Biotechnology and Cosunter Pharmaceutical, driving international collaboration of innovative drug candidates across the globe. He has 8+ years of experience in brokering transformative BD deals and driving high-impact pharmaceutical strategies, having orchestrated high-value licensing initiatives that advanced organizational goals and delivered cost-effective outcomes across Oncology, Ophthalmology, and other therapeutic areas.

About ACCESS ASIA Partnering Forum

ACCESS Asia Partnering Forum Online Showcase is scheduled to be held on September 25, 2025, 9:30 AM (China Standard Time) via Zoom.
This event will spotlight the 1st wave of 100 innovators, providing them with a global stage to showcase pipelines and connect with pharma, investors, and strategic partners worldwide.

Conference Name: ACCESS Asia Partnering Forum Online Showcase
Date & Time: September 25, 2025, 9:30 AM (China Standard Time)
View more information at: https://biotochina.org/